Abstract |
In-vitro susceptibility studies were performed on 99 clinical Staphylococcus aureus isolates. A total of 68 of 73 methicillin-resistant S. aureus and 2 of 26 methicillin-susceptible S. aureus were gentamicin-resistant ( gentamicin MIC range 16 to 1,024 microg/mL). All 70 gentamicin-resistant isolates contained the aac(6')-Ie-aph(2'')-Ia aminoglycoside resistance gene, and none possessed the aph(2'')-Ic or aph(2'')-Id aminoglycoside resistance genes. The arbekacin MIC for the 70 gentamicin-resistant isolates ranged from 0.25 to 4 microg/mL. The combination of arbekacin plus vancomycin produced synergistic killing against 12 of 13 gentamicin-resistant MRSA isolates. The combination of gentamicin plus vancomycin produced synergistic killing against 7 of the same 13 isolates. Arbekacin may prove useful when used in combination with vancomycin in treating infections caused by gentamicin-resistant MRSA.
|
Authors | I You, R Kariyama, M J Zervos, H Kumon, J W Chow |
Journal | Diagnostic microbiology and infectious disease
(Diagn Microbiol Infect Dis)
Vol. 36
Issue 1
Pg. 37-41
(Jan 2000)
ISSN: 0732-8893 [Print] United States |
PMID | 10744365
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Aminoglycosides
- Anti-Bacterial Agents
- DNA, Bacterial
- Gentamicins
- Dibekacin
- Vancomycin
- arbekacin
|
Topics |
- Aminoglycosides
- Anti-Bacterial Agents
(administration & dosage, pharmacology)
- Base Sequence
- DNA, Bacterial
- Dibekacin
(administration & dosage, analogs & derivatives)
- Drug Interactions
- Drug Resistance, Multiple
- Drug Therapy, Combination
(pharmacology)
- Gentamicins
(pharmacology)
- Humans
- Methicillin Resistance
- Microbial Sensitivity Tests
- Molecular Sequence Data
- Polymerase Chain Reaction
- Sensitivity and Specificity
- Staphylococcus aureus
(drug effects, isolation & purification)
- Vancomycin
(administration & dosage)
|